| scholarly article | Q13442814 |
| P50 | author | Luca Malorni | Q84044174 |
| P2093 | author name string | C De Angelis | |
| R Elledge | |||
| S De Placido | |||
| C K Osborne | |||
| G Arpino | |||
| S Hilsenbeck | |||
| P B Shetty | |||
| M F Rimawi | |||
| P2860 | cites work | Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status | Q27824865 |
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| Repeated observation of breast tumor subtypes in independent gene expression data sets | Q28131820 | ||
| Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype | Q28271274 | ||
| Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review | Q33561966 | ||
| Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes | Q33691211 | ||
| EGFR and cancer prognosis | Q34399312 | ||
| Triple-negative breast cancer: clinical features and patterns of recurrence | Q34658655 | ||
| Basal-like breast carcinomas: clinical outcome and response to chemotherapy | Q35770209 | ||
| Breast cancer classification and prognosis based on gene expression profiles from a population-based study | Q35918291 | ||
| Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States | Q37155632 | ||
| Triple-negative breast cancers are increased in black women regardless of age or body mass index | Q37208769 | ||
| Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel | Q37862646 | ||
| Molecular heterogeneity of triple-negative breast cancer and its clinical implications | Q37944122 | ||
| How basal are triple-negative breast cancers? | Q40105023 | ||
| Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. | Q40606719 | ||
| Growth factors. Clinical implications in breast cancer | Q40800342 | ||
| Measurement of progesterone receptor in human breast cancer biopsies | Q41487198 | ||
| Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas | Q42519640 | ||
| Cancer. Aneuploidy drives a mutator phenotype in cancer. | Q42936457 | ||
| Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients | Q43838214 | ||
| HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. | Q45946352 | ||
| Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity | Q46328432 | ||
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance | Q46689580 | ||
| Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. | Q51531354 | ||
| The Triple-Negative Subtype: New Ideas for the Poorest Prognosis Breast Cancer | Q57580751 | ||
| Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers | Q67519244 | ||
| Evaluation of estrogen receptor assays in human breast cancer tissue | Q67548485 | ||
| DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens | Q68255685 | ||
| Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry | Q69949773 | ||
| DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients | Q72282862 | ||
| Time-dependence of hazard ratios for prognostic factors in primary breast cancer | Q74582694 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 795-804 | |
| P577 | publication date | 2012-11-04 | |
| P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
| P1476 | title | Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up | |
| P478 | volume | 136 |
| Q48345502 | A functional BRCA1 coding sequence genetic variant contributes to prognosis of triple-negative breast cancer, especially after radiotherapy |
| Q39021766 | Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer. |
| Q64249067 | Alantolactone promotes ER stress-mediated apoptosis by inhibition of TrxR1 in triple-negative breast cancer cell lines and in a mouse model |
| Q90405867 | Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells |
| Q57112840 | Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis |
| Q47271244 | Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells |
| Q35185688 | Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer |
| Q41694184 | Crosstalk between stromal components and tumor cells of TNBC via secreted factors enhances tumor growth and metastasis |
| Q90657014 | Cytokines secreted by stromal cells in TNBC microenvironment as potential targets for cancer therapy |
| Q64117853 | Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study |
| Q94562952 | EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo |
| Q64119667 | GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer |
| Q33757639 | Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling. |
| Q54965602 | How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. |
| Q91810896 | Identification of potential key genes and pathways predicting pathogenesis and prognosis for triple-negative breast cancer |
| Q52407848 | Integrative network-based approach identifies central genetic and transcriptomic elements in triple-negative breast cancer. |
| Q92962964 | Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer |
| Q92641713 | Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling |
| Q48711808 | Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer |
| Q34570508 | Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study. |
| Q64226628 | Neighborhood Social Determinants of Triple Negative Breast Cancer |
| Q92476216 | Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study |
| Q28067436 | Novel therapeutic strategies for patients with triple-negative breast cancer |
| Q92716047 | Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer |
| Q37630473 | PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer |
| Q90387216 | Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer |
| Q38269204 | Preoperative 18F-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer |
| Q90666353 | Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer |
| Q96303036 | Radiomics Analysis of MRI for Predicting Molecular Subtypes of Breast Cancer in Young Women |
| Q92749855 | Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26 |
| Q90262361 | Role of mitochondria in rescuing glycolytically inhibited subpopulation of triple negative but not hormone-responsive breast cancer cells |
| Q90480621 | Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors |
| Q35796826 | Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug |
| Q89499655 | Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition |
| Q55422999 | The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. |
| Q37573454 | The neutrophil-to-lymphocyte ratio: a narrative review |
| Q47097677 | The role of BRCA status on prognosis in patients with triple-negative breast cancer |
| Q50287957 | Transcriptional profiles of different states of cancer stem cells in triple-negative breast cancer. |
| Q33769821 | Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease |
| Q37721791 | Tuberatolide B Suppresses Cancer Progression by Promoting ROS-Mediated Inhibition of STAT3 Signaling |
| Q64106473 | Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene |
| Q64890070 | Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. |
| Q58605694 | miR-3178 inhibits cell proliferation and metastasis by targeting Notch1 in triple-negative breast cancer |
Search more.